About Monte Rosa Therapeutics Inc
- Industry: Biotechnology
- Exchange: NASDAQ NMS - GLOBAL MARKET
- Country: US
- Website: https://www.monterosatx.com/
Frequently Asked Questions
What is the 52-week range for GLUE?
The 52-week high is $25.77 and the 52-week low is $7.235.
What is the P/E ratio for GLUE?
The P/E ratio data is currently unavailable.
What is the dividend yield for GLUE?
This company does not currently pay a dividend or the data is unavailable.
What is the Return on Equity (ROE)?
The trailing twelve months (TTM) Return on Equity is -43.31%.
What is the Net Profit Margin?
The Net Profit Margin (TTM) is -560.85%.
What is the Price to Book (P/B) Ratio?
The annual Price to Book ratio stands at 4.38.
Analyst Recommendation Trends
Wall Street analyst consensus for GLUE over the last few months:
Latest GLUE News
Monte Rosa Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
BOSTON, Oct. 02, 2026 (GLOBE NEWSWIRE) -- Monte Rosa Therapeutics, Inc. (Nasdaq: GLUE), a clinical-stage biotechnology company developing novel molecular glue degrader (MGD)-based medicines, today announced the grant of inducement equity awards to five newly hired non-executive employees as a material inducement to commencing their employment with the Company. The employees received, in the aggregate, non-qualified stock options to purchase 86,725 shares of Monte Rosa Therapeutics common stock,
Monte Rosa Therapeutics, Inc. (GLUE) Discusses GFORCE-1 Phase I Results for NEK7 Molecular Glue Degrader MRT-8102 in Cardiovascular Disease Risk Transcript
Monte Rosa Therapeutics, Inc. (GLUE) Discusses GFORCE-1 Phase I Results for NEK7 Molecular Glue Degrader MRT-8102 in Cardiovascular Disease Risk October 1,...
Monte Rosa Therapeutics Investigational Drug Shows Potential for Cardiovascular Disease
Monte Rosa Therapeutics reports positive Phase 1 trial data for MRT-8102 and outlines upcoming Phase 2 studies in inflammatory diseases.
Monte Rosa Therapeutics Announces Positive Results for MRT-8102 in GFORCE-1 Phase 1 Study Showing Normalization of Key Pathogenic Drivers of ASCVD in Subjects with Elevated CVD Risk
In obese subjects at elevated cardiovascular disease (CVD) risk, MRT-8102, a NEK7-directed molecular glue degrader in development for the treatment of NLRP3/IL-1-driven inflammatory diseases, normalized multiple atherosclerotic cardiovascular disease (ASCVD) pathogenic drivers of local plaque inflammation, thrombosis, and systemic inflammation Robust and sustained NEK7 degradation observed across 5 mg, 20 mg, and 40 mg once-daily dose levels, with similar biomarker reductions at all three doses
12 Health Care Stocks Moving In Thursday's Pre-Market Session
Gainers DataMEDS AI (NASDAQ:MEDS) stock moved upwards by 39.4% to $4.42 during Thursday's pre-market session. The company's market cap stands at $10.1 million. Stablecoin Development (AMEX:SDEV) shares moved
Monte Rosa Reports Data From GFORCE-1, Phase 1 Study Evaluating MRT-8102, NEK7-Directed MGD Being Developed For Treatment Of Inflammatory Conditions Driven By NEK7/NLRP3 Pathway
In obese subjects at elevated cardiovascular disease (CVD) risk, MRT-8102, a NEK7-directed molecular glue degrader in development for the treatment of NLRP3/IL-1-driven inflammatory diseases, normalized multiple
GLUE Stock Soars Over 20% Pre-Market: What's Driving the Surge?
Monte Rosa Therapeutics shares surged 20.03% premarket as investors awaited clinical data from its experimental heart-risk drug.
HC Wainwright & Co. Initiates Coverage On Monte Rosa Therapeutics with Buy Rating, Announces Price Target of $25
HC Wainwright & Co. analyst Mitchell S. Kapoor initiates coverage on Monte Rosa Therapeutics (NASDAQ:GLUE) with a Buy rating and announces Price Target of $25.
Why Vicor Shares Are Trading Higher By Around 12%; Here Are 20 Stocks Moving Premarket
Vicor shares surged 12% after raising Q3 growth guidance above 30%; Roze AI led gainers, while Corteva plunged 57% premarket.
These stocks are moving in today's after hours session
Wondering what's happening in today's after-hours session? Stay tuned for the latest updates on stock movements.
Monte Rosa Therapeutics to Present Results of MRT-8102 GFORCE-1 Phase 1 Study in Subjects with Elevated Cardiovascular Disease Risk
Conference call and webcast to be held at 8:00 a.m. ET on Oct. 1, 2026BOSTON, Sept. 30, 2026 (GLOBE NEWSWIRE) -- Monte Rosa Therapeutics, Inc. (Nasdaq: GLUE), a clinical-stage biotechnology company developing novel molecular glue degrader (MGD)-based medicines, today announced that management will host a live conference call and webcast on Thursday, October 1, at 8:00 a.m. ET. The webcast presentation will review clinical results from the GFORCE-1 Phase 1 study of the NEK7-directed MGD MRT-8102
12 Health Care Stocks Moving In Wednesday's After-Market Session
Gainers Monte Rosa Therapeutics (NASDAQ:GLUE) stock rose 9.7% to $13.09 during Wednesday's after-market session. The company's market cap stands at $1.0 billion. Filana Therapeutics (NASDAQ:FLNA) shares rose
Novartis (NVS) Just Handed Monte Rosa (GLUE) A $50M Milestone
On September 8, Monte Rosa Therapeutics (NASDAQ:GLUE) announced that Novartis (NYSE:NVS), its partner on a VAV1-targeted drug, had dosed the first patient in a Phase 2 trial of MRT-6160 (DDY391) for people with Sjögren’s disease. That single clinical checkpoint triggers a $50 million payment to Monte Rosa and marks just the first step in a […]
Wedbush Reiterates Outperform on Monte Rosa Therapeutics, Maintains $27 Price Target
Wedbush analyst Robert Driscoll reiterates Monte Rosa Therapeutics (NASDAQ:GLUE) with a Outperform and maintains $27 price target.
Top Midday Stories: GE Aerospace to Acquire Consolidated Precision Products; Qualcomm Issues Share Warrant to Amazon
All three major US stock indexes fell in late-morning trading Tuesday as oil prices climbed and inve
Monte Rosa Therapeutics Announces Milestone Achievement Associated with Initiation of Phase 2 Clinical Study for VAV1-directed Molecular Glue Degrader MRT-6160 (DDY391)
Phase 2 study to be conducted in participants with Sjögren’s disease Novartis conducting study under global exclusive development and commercialization license agreement with Monte Rosa Monte Rosa to receive milestone payment based on first patient visit of Phase 2 clinical study Additional studies expected to evaluate the potential of MRT-6160 (DDY391) across immune-mediated diseases; Monte Rosa eligible for additional Phase 2 study initiation milestones BOSTON, Sept. 08, 2026 (GLOBE NEWSWIRE)
Related Stocks (Peers)
Recent Insider Transactions
| Date | Name | Shares Changed | Price | Value |
|---|---|---|---|---|
| 2026-07-16 | Warmuth Markus | -9,500 | $23.1809 | $220,219 |
| 2026-07-15 | Champoux Jennifer | -4,351 | - | - |
| 2026-07-15 | Champoux Jennifer | -4,351 | $23.3808 | $101,730 |
| 2026-07-15 | Champoux Jennifer | +4,351 | $3.98 | $17,317 |
| 2026-07-06 | Townson Sharon | -6,000 | - | - |
| 2026-07-06 | Townson Sharon | -400 | $24.13 | $9,652 |
| 2026-07-06 | Townson Sharon | -5,600 | $23.2495 | $130,197 |
| 2026-07-06 | Townson Sharon | +6,000 | $6.14 | $36,840 |
| 2026-07-01 | Behbahani Ali | -15,000 | - | - |
| 2026-07-01 | Behbahani Ali | +15,000 | - | - |
| 2026-07-01 | Behbahani Ali | -1,000,000 | - | - |
| 2026-06-30 | Janku Filip | -5,407 | - | - |
| 2026-06-30 | Janku Filip | -5,407 | $24.5 | $132,472 |
| 2026-06-30 | Janku Filip | +5,407 | $13.41 | $72,508 |
| 2026-06-24 | Janku Filip | -30,000 | - | - |
| 2026-06-24 | Janku Filip | -30,000 | $21.4227 | $642,681 |
| 2026-06-24 | Janku Filip | +30,000 | $7.56 | $226,800 |
| 2026-06-23 | Janku Filip | -6,000 | - | - |
| 2026-06-23 | Janku Filip | -11,845 | $20.2214 | $239,522 |
| 2026-06-23 | Janku Filip | +6,000 | $7.56 | $45,360 |
| 2026-06-23 | Townson Sharon | -3,000 | - | - |
| 2026-06-23 | Townson Sharon | -3,000 | $20 | $60,000 |
| 2026-06-23 | Townson Sharon | +3,000 | $6.14 | $18,420 |
| 2026-06-23 | Champoux Jennifer | -2,175 | - | - |
| 2026-06-23 | Champoux Jennifer | -2,175 | $20 | $43,500 |
| 2026-06-23 | Champoux Jennifer | +2,175 | $3.98 | $8,657 |
| 2026-06-11 | Skvarka Jan | +25,800 | - | - |
| 2026-06-11 | Hughes Eric A | +25,800 | - | - |
| 2026-06-11 | Blackwell Kimberly | +25,800 | - | - |
| 2026-06-11 | Siu Christine | +25,800 | - | - |
| 2026-06-11 | Manning Anthony M. | +25,800 | - | - |
| 2026-06-11 | Behbahani Ali | +25,800 | - | - |
| 2026-06-11 | SCHIFF ANDREW N | +25,800 | - | - |
| 2026-06-01 | Warmuth Markus | -468 | $19.7262 | $9,232 |
| 2026-06-01 | Warmuth Markus | -4,998 | $19.412 | $97,021 |
| 2026-05-29 | Townson Sharon | -6,000 | - | - |
| 2026-05-29 | Townson Sharon | -6,000 | $19.87 | $119,220 |
| 2026-05-29 | Townson Sharon | +6,000 | $6.14 | $36,840 |
| 2026-05-27 | Champoux Jennifer | -2,175 | - | - |
| 2026-05-27 | Champoux Jennifer | -2,175 | $20 | $43,500 |
| 2026-05-27 | Champoux Jennifer | +2,175 | $3.98 | $8,657 |
| 2026-05-22 | Champoux Jennifer | -2,176 | - | - |
| 2026-05-22 | Champoux Jennifer | -2,176 | $19 | $41,344 |
| 2026-05-22 | Champoux Jennifer | +2,176 | $3.98 | $8,660 |
| 2026-05-21 | Manning Anthony M. | -10,000 | - | - |
| 2026-05-21 | Manning Anthony M. | -10,000 | $18.01 | $180,100 |
| 2026-05-21 | Manning Anthony M. | +10,000 | $4.16 | $41,600 |
| 2026-05-01 | Warmuth Markus | -5,467 | $18.922 | $103,447 |
| 2026-04-14 | Warmuth Markus | -8,000 | $17.6406 | $141,125 |
| 2026-04-09 | Nickson Philip | -5,845 | $17.6925 | $103,413 |
| 2026-04-06 | Bowen Matthew | +19,500 | - | - |
| 2026-04-06 | Bowen Matthew | +4,300 | - | - |
| 2026-03-04 | Dunn Edmund | -139 | $17.96 | $2,496 |
| 2026-03-02 | Warmuth Markus | -5,466 | $17.9243 | $97,974 |
| 2026-03-02 | Dunn Edmund | -536 | - | - |
| 2026-03-02 | Dunn Edmund | -536 | $17.5 | $9,380 |
| 2026-03-02 | Dunn Edmund | +536 | $13.41 | $7,188 |
| 2026-02-27 | Dunn Edmund | -25,164 | - | - |
| 2026-02-27 | Dunn Edmund | -25,164 | $18.1015 | $455,506 |
| 2026-02-27 | Dunn Edmund | +25,164 | $13.41 | $337,449 |
| 2026-02-23 | Janku Filip | -9,189 | $19.4973 | $179,161 |
| 2026-01-07 | Warmuth Markus | -309 | $24.5736 | $7,593 |
| 2026-01-07 | Warmuth Markus | -1,450 | $23.8762 | $34,620 |
| 2026-01-07 | Warmuth Markus | -3,707 | $23.2422 | $86,159 |
| 2026-01-05 | Nickson Philip | -3,155 | $15.17 | $47,861 |
| 2026-01-05 | Champoux Jennifer | -2,629 | $15.17 | $39,882 |
| 2026-01-05 | Dunn Edmund | -1,039 | $15.17 | $15,762 |
| 2026-01-05 | Warmuth Markus | -10,135 | $15.17 | $153,748 |
| 2026-01-05 | Janku Filip | -3,155 | $15.17 | $47,861 |
| 2026-01-05 | Townson Sharon | -3,155 | $15.17 | $47,861 |
| 2026-01-02 | Nickson Philip | +126,000 | - | - |
| 2026-01-02 | Nickson Philip | +28,000 | - | - |
| 2026-01-02 | Champoux Jennifer | +158,000 | - | - |
| 2026-01-02 | Champoux Jennifer | +35,000 | - | - |
| 2026-01-02 | Warmuth Markus | +406,000 | - | - |
| 2026-01-02 | Warmuth Markus | +90,000 | - | - |
| 2026-01-02 | Janku Filip | +139,000 | - | - |
| 2026-01-02 | Janku Filip | +31,000 | - | - |
| 2026-01-02 | Townson Sharon | +158,000 | - | - |
| 2026-01-02 | Townson Sharon | +35,000 | - | - |